Evidence map›Paper›PMID 34342000›Full record

ReviewAnnals of the New York Academy of Sciences2021

Harnessing rare variants in neuropsychiatric and neurodevelopment disorders-a Keystone Symposia report.

Jennifer Cable, Ryan H Purcell, Elise Robinson, Jacob A S Vorstman, Wendy K Chung, John N Constantino, Stephan J Sanders, Mustafa Sahin, Ricardo E Dolmetsch, Bina Maniar Shah and 4 more

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jennifer CablePhD Science Writer, New York, New York.
Ryan H PurcellDepartment of Cell Biology, Emory University School of Medicine, Atlanta, Georgia.
Elise RobinsonStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Jacob A S VorstmanDepartment of Psychiatry and the Centre for Applied Genomics, Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
Wendy K ChungDepartments of Pediatrics and Medicine, Columbia University, New York, New York.
John N ConstantinoDepartment of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.
Stephan J SandersDepartment of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California.
Mustafa SahinRosamund Stone Zander Translational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Ricardo E DolmetschuniQure, Lexington, Massachusetts.
Bina Maniar ShahProject 8p Foundation, Commission on Novel Technologies for Neurodevelopmental CNVs, New York, New York.
Audrey ThurmNeurodevelopmental and Behavioral Phenotyping, NIMH, National Institutes of Health, Bethesda, Maryland.
Christa L MartinAutism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.
Carrie E BeardenIntegrative Center for Neurogenetics, Departments of Psychiatry and Biobehavioral Science and Psychology, University of California Los Angeles, Los Angeles, California.
Jennifer G MulleDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Toward better characterization and clinical trial readiness for targeting neuropsychiatric manifestations in PTEN pathogenic variantsU54NS092090 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI M. Pilar Trelles · 2014 to 2026
$20.1M
WUIDDRC Supplement-Supporting the health and well-being of children with intellectual and developmental disability during COVID-19 pandemicP50HD103525 · NICHD · WASHINGTON UNIVERSITY · PI JEFFREY D MILBRANDT · 2020 to 2026
$15.5M
Neurodevelopmental and Behavioral Phenotyping ZICMH002961 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI THURM, AUDREY · 2017 to 2025
$12.6M
Leveraging rare genetic etiologies to advance knowledge and treatment of neurpsychiatric disordersU01MH119705 · NIMH · GEISINGER CLINIC · PI LEDBETTER, DAVID H., MARTIN, CHRISTA LESE · 2019 to 2023
$9.2M
Neurodevelopment and Psychosis in the 22q11.2 Deletion SyndromeR01MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2010 to 2020
$6.2M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI CHEN, CHINFEI · 2016 to 2020
$5.2M
Modeling the Human Neuronal Phenotype of the Schizophrenia-Associated 3q29 deletionR01MH110701 · NIMH · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI MULLE, JENNIFER GLADYS · 2017 to 2021
$3.2M
Neurodevelopment and Psychosis in the 22q11.2 Copy Number VariantsR37MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CARRIE E BEARDEN · 2023 to 2026
$2.9M
Neuroimaging of the schizophrenia-associated 3q29 deletionR01MH118534 · NIMH · EMORY UNIVERSITY · PI MULLE, JENNIFER GLADYS, SHULTZ, SARAH · 2019 to 2023
$1.9M
3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disordersU01MH119736 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2019 to 2024
$1.2M
Neurobiological basis of dysconnectivity in a genetic risk model of psychosisR21MH116473 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E, GOZZI, ALESSANDRO · 2018 to 2019
$366k
Intramural NIH HHS ZIC MH002961NCATS NIH HHS UL1 TR001863NICHD NIH HHS P50 HD103525NICHD NIH HHS U54 HD090255NIMH NIH HHS F32 MH124273NIMH NIH HHS R01 MH085953NIMH NIH HHS R01 MH110701NIMH NIH HHS R01 MH118534NIMH NIH HHS R21 MH116473NIMH NIH HHS R37 MH085953NIMH NIH HHS U01 MH119705NIMH NIH HHS U01 MH119736NINDS NIH HHS U54 NS092090
6 · The paper itself

Abstract

Neurodevelopmental neuropsychiatric disorders, such as autism spectrum disorder and schizophrenia, have strong genetic risk components, but the underlying mechanisms have proven difficult to decipher. Rare, high-risk variants may offer an opportunity to delineate the biological mechanisms responsible more clearly for more common idiopathic diseases. Indeed, different rare variants can cause the same behavioral phenotype, demonstrating genetic heterogeneity, while the same rare variant can cause different behavioral phenotypes, demonstrating variable expressivity. These observations suggest convergent underlying biological and neurological mechanisms; identification of these mechanisms may ultimately reveal new therapeutic targets. At the 2021 Keystone eSymposium "Neuropsychiatric and Neurodevelopmental Disorders: Harnessing Rare Variants" a panel of experts in the field described significant progress in genomic discovery and human phenotyping and raised several consistent issues, including the need for detailed natural history studies of rare disorders, the challenges in cohort recruitment, and the importance of viewing phenotypes as quantitative traits that are impacted by rare variants.

Indexed as

PenetranceResearch ReportCongresses as TopicGenetic VariationHumansMental DisordersNeurodevelopmental Disorders16p11.2 deletion22q11.2 deletion3q29 deletionautismautism heterogeneityautism spectrum disordercopy number variantintellectual disabilityneurodevelopmental disordersneuropsychiatric disorderspolygenic risk scorerare variantsschizophreniaTSC

Identifiers

PMID34342000
PMCPMC8688183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.